Am J Transplant, Volume 18, Suppl 3 Archives - Page 135 of 211 - ATC Abstracts

2018 American Transplant Congress
Accepting a DCD Liver May Improve Patient Survival Compared to Waiting for a Non-DCD Liver
A. Wey,¹ N. Salkowski,¹ J. Lake,² W. Kim,³ B. Kasiske,¹ A. Israni,¹ J. Snyder.¹
¹Scientific Registry of Transplant Recipients, Minneapolis; ²Univ of Minnesota, Minneapolis; ³Stanford University, Palo Alto.
Only ~50% of liver candidates undergo deceased donor transplant; 17% die on the waiting list and 20% are removed from the list as too sick…
2018 American Transplant Congress
Cost Effectiveness of Hepatitis C Positive Donor Kidney Transplantation for Hepatitis C Negative Recipients with Concomitant Direct-Acting Anti-Viral Therapy
G. Gupta, Y. Zhang, H. Kale, N. Carroll, R. Sterling.
Virginia Commonwealth University, Richmond.
Background: The development of direct acting antiviral (DAA) therapy for hepatitis C virus (HCV) could allow for safe and effective treatment following renal transplantation (RT).…
2018 American Transplant Congress
Using the Explore Transplant Ontario Program to Increase Transplant Knowledge and Readiness among Patients on Maintenance Dialysis
D. Belenko,¹ C. Richardson,¹ V. Gupta,¹ T. Ahmed, N. Edwards, M. Novak,² J. Peipert,³ A. Waterman, I. Mucsi.
¹Multi-Organ Transplant Program, Department of Surgery, University Health Network, Toronto, ON, Canada; ²Department of Psychiatry, University of Toronto, Toronto, ON, Canada; ³David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
IntroductionKidney transplantation (KT) is the preferred treatment for patients with End-Stage Kidney Disease (ESKD), yet many potentially eligible patients do not act to pursue KT.…
2018 American Transplant Congress
CFZ533, a New Anti-CD40 mAB Demonstrates Comparable Efficacy and Better Renal Function versus Tacrolimus in De-Novo CNI-Free Kidney Transplantation
B. Nashan,¹ H. Tedesco,¹ M. van den Hoogen,¹ S. Berger,¹ D. Cibrik,¹ S. Mulgaonkar,¹ D. Leeser,¹ R. Alloway,¹ A. Patel,¹ J. Pratschke,¹ C. Sommerer,¹ A. Wiseman,¹ A. van Zuilen,¹ U. Laessing,² J. Rush,² B. Haraldsson,² O. Witzke.¹
¹CFZ533 Study Group, Basel, Switzerland; ²Novartis Pharma, Basel, Switzerland.
Purpose: To assess the potential of CFZ533 as primary immunosuppressant in a calcineurin(CNI)-free regimen in de novo kidney transplant (KTx) patients(pts).Method: CFZ533 is a new,…
2018 American Transplant Congress
Donor-Specific Antibody Mediates Chronic, but Not Acute, Kidney Allograft Rejection in the Absence of Natural Killer Cells
T. Yagisawa, N. Dvorina, A. Valujskikh, W. Baldwin 3rd, R. Fairchild.
Immunology and Glickman Urological Institute, Cleveland Clinic, Cleveland, OH.
The incidence of antibody-mediated kidney graft rejection continues to increase. We previously reported that dysregulated donor-specific antibody (DSA) responses were induced in B6.CCR5-/- mice transplanted…
2018 American Transplant Congress
Impact of Rapid Discontinuation of Prednisone on Kidney Transplant Outcomes in At-Risk Subpopulations: An OPTN/SRTR Analysis
D. Vock,¹ A. Matas.²
¹Public Health, U of MN, Mpls, MN; ²Surgery, U of MN, Mpls, MN.
Objective: Successful RDP (rapid discontinuation of prednisone <1 week post-tx) after kidney transplant (KTx) has been reported for low-risk populations. We studied the impact of…
2018 American Transplant Congress
Early Considerations for Deceased Donor Chains
A. Toll,¹ R. Leishman,¹ V. Casingal,² M. Aeder,³ T. Sandholm,⁴ N. Turgeon.⁵
¹UNOS, Richmond, VA; ²Carolinas HeathCare Sys, Charlotte, NC; ³Univ Hosp Med Ctr, Cleveland, OH; ⁴Carnegie Mellon Univ, Pittsburgh, PA; ⁵Emory Univ, Atlanta, GA.
Background: The potential use of deceased kidney donors (DDs) to initiate kidney paired donation (KPD) chains (DD chains) has been of interest to the transplant…
2018 American Transplant Congress
Comparison of Recipients with Early and Late Presenting Polyomavirus Nephropathy (PVN) with Regard to Histological Findings and Graft Survival: What is the Influence of CD4/CD8 Ratio on the Presenting Time of PVN
B. Ozdemir,¹ S. Ayva,¹ A. Terzi,¹ A. Ok Atilgan,¹ E. Akcay,¹ E. Ayvazoglu Soy,² F. Ozdemir,³ M. Haberal.²
¹Pathology, Baskent University, Ankara, Turkey; ²Transplantation, Baskent University, Ankara, Turkey; ³Nephrology, Baskent University, Ankara, Turkey.
Introduction: PVN is a common complication occurring around 12 mo after renal transplant (RT). We aimed to explore the differences between early and late-onset PVN…
2018 American Transplant Congress
Pancreas Transplant Recipients with End-Stage Renal Disease Benefit from Kidney Transplantation
Y. Tang, Z. Zhu, S. Huang, Z. Zhang, W. Ju, Z. Guo, X. He, G. Chen.
Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Background: End-stage renal disease (ESRD) has been shown after pancreas transplant alone (PTA), however, the benefit of kidney transplantation (KT) in PTA recipients with ESRD…
2018 American Transplant Congress
Shared HLA Specificities between the Blood and Transplant Donor Increases the Risk of De Novo DSA Development Following Blood Transfusion in Transplant Recipients
S. Hassan,¹ F. Regan,² C. Brown,³ A. Harmer,² N. Anderson,² E. Santos,⁴ P. Brookes,⁴ D. Taube,¹ M. Willicombe.¹
¹Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, United Kingdom; ²Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom; ³Histocompatibility and Immunogenetics, NHS Blood and Transplant, London, United Kingdom; ⁴Histocompatibility and Immunogenetics, Imperial College Healthcare NHS Trust, London, United Kingdom.
Introduction: Blood transfusions post-transplant have been shown to be associated with the development of de novo DSA and inferior allograft outcomes. The mechanisms behind this…